Predictors of early worsening after switch to aripiprazole: A randomized, controlled, open-label study

Clinical Drug Investigation

Volumn 30, Issue 3, 2010, Pages 187-193

  Pae, Chi Un ^a,b   Chiesa, Alberto ^c   Mandelli, Laura ^c   Patkar, Ashwin A ^b   Gibiino, Sara ^c   Serretti, Alessandro ^c  

^a The Catholic University of Korea   (South Korea)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

^c UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

AMISULPRIDE; ARIPIPRAZOLE; DOPAMINE 2 RECEPTOR; OLANZAPINE; QUETIAPINE; RISPERIDONE;

ADULT; ARTICLE; BRIEF PSYCHIATRIC RATING SCALE; CLINICAL GLOBAL IMPRESSION SCALE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE EXACERBATION; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; OPEN STUDY; PREDICTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCHIZOPHRENIA;

ANTIPSYCHOTIC AGENTS; DRUG ADMINISTRATION SCHEDULE; HUMANS; MALE; PIPERAZINES; PSYCHIATRIC STATUS RATING SCALES; QUINOLONES; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 77249155576     PISSN: 11732563     EISSN: 11791918     Source Type: Journal    
DOI: 10.2165/11533060-000000000-00000     Document Type: Article

References (29)

1. National Institute for Clinical Excellence. Schizophrenia: core interventions in the treatment and management of schizophrenia in primary and secondary care. National Collaborating Centre for Mental Health (NCCMH). London: NICE, 2003 Mar 25
2. Leslie DL, Rosenheck RA. From conventional to atypical antipsychotics and back: dynamic processes in the diffusion of newmedications. Am J Psychiatry 2002; 159 (9): 1534-1540
3. Covell NH, Jackson CT, Evans AC, et al. Antipsychotic prescribing practices in Connecticut's public mental health system: rates of changing medications and prescribing styles. Schizophrenia Bull 2002; 28 (1): 17-29
4. Rothbard AB, Kuno E, Foley K. Trends in the rate and type of antipsychotic medications prescribed to persons with schizophrenia. Schizophrenia Bull 2003; 29 (3): 531-540
5. Kinon BJ, BassonBR,Gilmore JA, et al. Strategies for switching from conventional antipsychotic drugs or risperidone to olanzapine. J Clin Psychiatry 2000; 61 (11): 833-840
6. Casey DE, Carson WH, Saha AR, et al. Switching patients to aripiprazole from other antipsychotic agents: a multicenter randomized study. Psychopharmacology (Berlin) 2003; 166 (4): 391-399
7. Takeuchi H, Suzuki T, Uchida H, et al. A randomized, open-label comparison of 2 switching strategies to aripiprazole treatment in patients with schizophrenia: add-on, wait, and tapering of previous antipsychotics versus addon and simultaneous tapering. J Clin Psychopharmacol 2008; 28 (5): 540-543
8. Pae CU, Serretti A, Chiesa A, et al. Immediate versus gradual suspension of previous treatments during switch to aripiprazole: results of a randomized, open label study. Eur Neuropsychopharmacol 2009; 19 (8): 562-570
9. Henderson DC, Nasrallah RA, Goff DC. Switching from clozapine to olanzapine in treatment-refractory schizophrenia: safety, clinical efficacy, and predictors of response. J Clin Psychiatry 1998; 59 (11): 585-588
10. Shajahan P, Macrae A, Bashir M, et al. Who responds to aripiprazole in clinical practice? An observational study of combination versus monotherapy. J Psychopharmacol 2008; 22 (7): 778-783
11. El-Sayeh HG, Morganti C, Adams CE. Aripiprazole for schizophrenia: systematic review. Br J Psychiatry 2006; 189: 102-108
12. Bhattacharjee J, El-Sayeh HG. Aripiprazole versus typical antipsychotic drugs for schizophrenia. Cochrane Database Syst Rev 2008; (3): CD006617
13. Mago R. Proposed strategies for successful clinical management with aripiprazole. Expert Opin Pharmacother 2008; 9 (8): 1279-1290
14. Casey D, Daniel D, Wassef A, et al. Effect of divalproex combined with olanzapine or risperidone in patients with an acute exacerbation of schizophrenia. Neuropsychopharmacology 2003; 28 (1): 182-192
15. Ramaswamy S, Vijay D, William M, et al. Aripiprazole possibly worsens psychosis. Int Clin Psychopharmacol 2004; 19 (1): 45-48
16. Di Lorenzo R, Amoretti A, Forghieri M, et al. Aripiprazole: effectiveness and safety under naturalistic conditions. Exp Clin Psychopharmacol 2007; 15 (6): 569-575
17. Kerwin R, Millet B, Herman E, et al. A multicentre, randomized, naturalistic, open-label study between aripiprazole and standard of care in the management of community-treated schizophrenic patients: Schizophrenia Trial of Aripiprazole (STAR) study. Eur Psychiatry 2007; 22 (7): 433-443
18. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th ed. Washington, DC: American Psychiatric Association, 1994
19. GuyW. Clinical Global Impression. In: Assessment manual for psychopharmacology. Washington, DC: Department of Health Education and Welfare, 1976: 217-222
20. Flemenbaum A, Zimmermann RL. Inter- and intra-rater reliability of the Brief Psychiatric Rating Scale. Psychol Rep 1973; 32 (3): 783-792
21. Andreasen N. Scale for the assessment of negative symptoms. Iowa City (IO): University of Iowa, 1983
22. Simpson GM, Angus JW. A rating scale for extrapyramidal side effects. Acta Psychiatr Scand Suppl 1970; 21: 211-219
23. Barnes TR. A rating scale for drug-induced akathisia. Br J Psychiatry 1989; 154: 672-676
24. Branch PR. Abnormal involuntarymovement scale (AIMS). Early Clin Drug Eval Unit Intercom 1975; 4 (1): 3-6
25. Rivas-Vasquez RA. Aripiprazole: a novel antipsychotic with dopamine-stabilising properties. Professional Psychol: Res Pract 2003; 34: 108-111
26. Raja M. Improvement or worsening of psychotic symptoms after treatment with low doses of aripiprazole. Int J Neuropsychopharmacol 2007; 10: 107-110
27. Reeves RR, Mack JE. Worsening schizoaffective disorder with aripiprazole. Am J Psychiatry 2004; 161 (7): 1308
28. Travis MJ, Burns T, Dursun S, et al. Aripiprazole in schizophrenia: consensus guidelines. Int J Clin Pract 2005; 59 (4): 485-495
29. Takeuchi H, Uchida H, Suzuki T, et al. Predictors of clinical worsening after a switch to aripiprazole in patients with schizophrenia: a 1-year naturalistic follow-up study. J Clin Psychopharmacol 2009; 29 (4): 394-395